Showing 8031-8040 of 8832 results for "".
- Novan Has Guidance Meeting with FDA on SB204https://practicaldermatology.com/news/novan-has-guidance-meeting-with-fda-on-sb204/2458040/Novan, Inc. is eyeing an additional pivotal trial for its investigational treatment for acne vulgaris, SB204. The company concluded a guidance meeting with the FDA regarding SB204 in which the agency advised that an additional pivotal trial should be conducted. Given the need for the ad
- Dove: Women's Shower Routines May Do More Harm Than Goodhttps://practicaldermatology.com/news/dove-womens-shower-routines-may-do-more-harm-than-good/2458043/Close to 80 percent of dermatologists believe women often focus on facial skincare, but neglect body skincare, according to new research from Dove. What’s more, 69 percent of dermatologists report that many women use gentle facial c
- New Label Reflects Sustained Response for Sun Pharma's Odomzo in BCChttps://practicaldermatology.com/news/new-label-reflects-sustained-response-for-sun-pharmas-odomzo-in-bcc/2458045/Sun Pharma’s new Odomzo® (Sonidegib) label incorporates long-term data showing sustained duration of response of 26 months in treatment of locally advanced basal cell carcinoma. Odomzo® is an oral hedgehog inhibitor indicated for t
- Eva Genel Named Director of Research and Development, Skincare at Silk Therapeuticshttps://practicaldermatology.com/news/eva-genel-named-director-of-research-and-development-skincare-at-silk-therapeutics/2458047/Eva Genel is the new Director of Research and Development, Skincare at Silk Therapeutics Inc., a specialty biomaterials company. In this new role, Genel's key responsibilities include designing and assessing clean, skincare formulations, o
- U.K Survey Reveals Eczema Treatment Knowledge Gaphttps://practicaldermatology.com/news/survey-reveals-eczema-treatment-knowledge-gap/2458049/Two thirds of UK eczema patients don’t understand that bacteria play a crucial role in their condition despite studies showing that Staphylococcus aureus is present on the skin in of more than 70 percent of patients, according to research from
- SkinCeuticals Launches Two New Cosmeceutical Cleansershttps://practicaldermatology.com/news/skinceuticals-launches-two-new-cosmeceutical-cleansers/2458048/SkinCeuticals is launching two new cleansers: Replenishing Cleanser and Smoothing Cleanser. What’s more, the original cleansers are all being repacked and reformulated. The new Replenishing Cleanser and Soothing Cleanser join SkinCeuticals&
- Happy 70th Cetaphil!https://practicaldermatology.com/news/happy-70th-cetaphil/2458051/Cetaphil is turning 70! To celebrate this milestone birthday, which takes place on Sept. 19, Cetaphil will launch a series of initiatives including: A 70-hour flash sale across retail partners nationwide running from September 17, 2017
- Five-Year Data Show Sustained Efficacy, Safety for Cosentyxhttps://practicaldermatology.com/news/five-year-data-show-sustained-efficacy-safety-for-cosentyx/2458054/Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase III data. These data were presented for
- IPC, Others Call for Creation of Worldwide Psoriasis Databasehttps://practicaldermatology.com/news/ipc-others-call-for-creation-of-worldwide-psoriasis-database/2458055/A new report calls for the creation of a web-based Global Psoriasis Atlas (GPA) database that will document the prevalence and incidence of psoriasis worldwide. The report, entitled "Global State of Psoriasis Epidemiology: A Workshop Report,
- Lilly to Present New Data for Olumiant® and Taltz® at EADVhttps://practicaldermatology.com/news/lilly-to-present-new-data-for-olumiant-and-taltz-eadv/2458060/Eli Lilly and Company will present Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the treatment of moderate-to-severe atopic dermatitis (Lilly and Incyte Corporation are partners on the develo